<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196596</url>
  </required_header>
  <id_info>
    <org_study_id>TAVIguide</org_study_id>
    <nct_id>NCT03196596</nct_id>
  </id_info>
  <brief_title>Added Value of Patient-specific Computer Simulation in Transcatheter Aortic Valve Implantation (TAVI)</brief_title>
  <acronym>TAVIguide</acronym>
  <official_title>The Value of Patient-specific Computer Simulation in the Planning of TAVI With the Self-expanding Evolut R Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>feops</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardialysis B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation is increasingly used to treat patients with severe
      aortic stenosis who are at increased risk for surgical aortic valve replacement and is
      projected to be the preferred treatment modality. As patient selection and operator
      experience have improved, it is hypothesised that device-host interactions will play a more
      dominant role in outcome. This, in combination with the increasing number of valve types and
      sizes, confronts the physician with the dilemma to choose the valve that best fits the
      individual patient. This necessitates the availability of pre-procedural computer simulation
      that is based upon the integration of the patient-specific anatomy, the physical and
      (bio)mechanical properties of the valve and recipient anatomy derived from in-vitro
      experiments. Patient-specific computer simulation may improve outcome of TAVI by proposing
      the valve size that best fits the individual patient.

      The aim of this study is to assess the added value of patient-specific computer simulation in
      valve size selection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Decision 1- Valve size decision based on pre TAVI MSCT</measure>
    <time_frame>an average of 2 days before TAVI, before TAVI and computer simulation</time_frame>
    <description>Valve size decision based on pre TAVI Multislice Computed Tomography (MSCT), which is performed in all patients referred for TAVI in accordance to clinical routine, during the heart team meeting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decision 2- Valve size decision after knowledge of the computer simulation results</measure>
    <time_frame>an average of 1 day before TAVI, before TAVI but after computer simulation</time_frame>
    <description>Valve size decision after availability of the results of computer simulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decision 3- Change of initial valve size decision during TAVI</measure>
    <time_frame>an average of 5 minutes after TAVI, directly after TAVI</time_frame>
    <description>Change of valve size decision during TAVI due to computer simulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decision 3- Change of initial depth of implantation strategy during TAVI</measure>
    <time_frame>an average of 5 minutes after TAVI, directly after TAVI</time_frame>
    <description>Change of depth of implantation strategy during TAVI due to computer simulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of implantation target</measure>
    <time_frame>an average of 2 days before TAVI, before TAVI and computer simulation</time_frame>
    <description>Initial depth of implantation strategy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of implantation target 2</measure>
    <time_frame>an average of 1 day before TAVI, before TAVI but after computer simulation</time_frame>
    <description>Depth of implantation strategy after availability of computer simulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic regurgitation</measure>
    <time_frame>an average of 4 days after TAVI, at hospital discharge</time_frame>
    <description>To compare the predicted (simulation) and observed degree of aortic regurgitation (echo post TAVI - Valve Academic Research Consortium (VARC-2) criteria for aortic regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between predicted contact pressure and observed new conduction abnormality</measure>
    <time_frame>an average of 4 days after TAVI, at hospital discharge</time_frame>
    <description>To compare the predicted maximum contact pressure, contact pressure index and conduction abnormalities with the observed occurrence of new conduction abnormalities after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>an average of 4 days after TAVI, at hospital discharge</time_frame>
    <description>To assess the incidence of Major Adverse Cardiovascular and Cerebrovascular Event (MACCE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the aforementioned outcome measures in a prospective group in whom no computer simulation will be perfomed</measure>
    <time_frame>an average of 4 days after TAVI, at hospital discharge</time_frame>
    <description>To compare the clinical based valve size decision and the angiographic and echocardiographic valve performance, depth of implantation, new conduction disorders and MACCE in a prospectively collected group of patients in whom no computer simulation will be performed</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Computer simulation</arm_group_label>
    <description>Patients in whom a computer simulation model will be obtained based on pre procedural CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective compare group</arm_group_label>
    <description>Patients in whom no computer simulation model will be obtained</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Computer simulation</intervention_name>
    <description>In these patients, a computer simulation model will be obtained based on pre procedural CT</description>
    <arm_group_label>Computer simulation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with native severe aortic valve stenosis accepted for TAVI with the self-expanding
        Evolut R Valve by the local heart team
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Native severe aortic valve stenosis

          -  Planned for TAVI with the Evolut R Valve

        Exclusion Criteria:

          -  Bicuspid aortic valve

          -  Extensive subannular calcifications

          -  Non-transfemoral access

          -  Poor CT quality

          -  Lack of written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter PT de Jaegere, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter PT de Jaegere, MD, PhD</last_name>
    <phone>+31107035656</phone>
    <email>p.dejaegere@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nahid El Faquir, MD</last_name>
    <phone>+31107038896</phone>
    <email>n.elfaquir@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Bosmans, MD, PhD</last_name>
      <phone>+32 3 821 5 56</phone>
      <email>johan.bosmans@uantwerpen.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ole De Backer, MD, PhD</last_name>
      <phone>+45 35457086</phone>
      <email>ole.debacker@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Gilard, MD, PhD</last_name>
      <phone>+33 2 98 34 75 03</phone>
      <email>martine.gilard@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Dumonteil, MD, PhD</last_name>
      <phone>+33 5 62 21 31 31</phone>
      <email>ndumonteil@clinique-pasteur.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne-Heart Center</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanja Rudolph, MD, PhD</last_name>
      <phone>+49 221 47832396</phone>
      <email>tanja.rudolph@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Azeem Latib, MD, PhD</last_name>
      <phone>+39 02 26431</phone>
      <email>alatib@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter PT de Jaegere, MD, PhD</last_name>
      <phone>+31107035656</phone>
      <email>p.dejaegere@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nahid El Faquir, MD</last_name>
      <phone>+31107038896</phone>
      <email>n.elfaquir@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Schultz C, Rodriguez-Olivares R, Bosmans J, Lefèvre T, De Santis G, Bruining N, Collas V, Dezutter T, Bosmans B, Rahhab Z, El Faquir N, Watanabe Y, Segers P, Verhegghe B, Chevalier B, van Mieghem N, De Beule M, Mortier P, de Jaegere P. Patient-specific image-based computer simulation for theprediction of valve morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards SAPIEN valve. EuroIntervention. 2016 Jan 22;11(9):1044-52. doi: 10.4244/EIJV11I9A212.</citation>
    <PMID>26788707</PMID>
  </reference>
  <reference>
    <citation>de Jaegere P, De Santis G, Rodriguez-Olivares R, Bosmans J, Bruining N, Dezutter T, Rahhab Z, El Faquir N, Collas V, Bosmans B, Verhegghe B, Ren C, Geleinse M, Schultz C, van Mieghem N, De Beule M, Mortier P. Patient-Specific Computer Modeling to Predict Aortic Regurgitation After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2016 Mar 14;9(5):508-12. doi: 10.1016/j.jcin.2016.01.003.</citation>
    <PMID>26965945</PMID>
  </reference>
  <reference>
    <citation>El Faquir N, Ren B, Van Mieghem NM, Bosmans J, de Jaegere PP. Patient-specific computer modelling - its role in the planning of transcatheter aortic valve implantation. Neth Heart J. 2017 Feb;25(2):100-105. doi: 10.1007/s12471-016-0923-6. Review.</citation>
    <PMID>27888494</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>P de Jaegere</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Computer simulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

